OncoMatch/Leukemia — Chronic Lymphocytic (CLL)/TP53 / 17p deletion
Leukemia — Chronic Lymphocytic (CLL)TP53 / 17p deletion Clinical Trials
TP53 mutation and/or 17p deletion occur in approximately 5–10% of treatment-naive CLL and up to 40% of relapsed/refractory disease, defining high-risk biology with resistance to chemoimmunotherapy. BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) and venetoclax-based regimens are effective in TP53-altered CLL regardless of deletion status. Trials investigate fixed-duration BTK/BCL2 combination regimens, novel BTK degraders, and CAR-T approaches for TP53-mutant CLL.
Top recruiting TP53 / 17p deletion Leukemia — Chronic Lymphocytic (CLL) trials
Ranked by phase and US site count. See all 8 trials matched to your profile →
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Loxo Oncology, Inc.
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
German CLL Study Group
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Merck Sharp & Dohme LLC
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Memorial Sloan Kettering Cancer Center
Browse other molecular targets with active Leukemia — Chronic Lymphocytic (CLL) trials.